A big legal victory across the Atlantic Ocean was the news propelling Moderna (MRNA 15.94%) stock to a significant price surge on Hump Day. The win by the company, best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during the trading session. By contrast, the S&P 500 (^GSPC 1.12%) could only muster a 1.1% gain.
Earlier that day, a court in Düsseldorf, Germany ruled that a COVID patent held by Moderna had been violated by a pair of rivals, American pharmaceutical giant Pfizer and its partner, German biotech BioNTech. The two had collaborated on developing and bringing to market another go-to COVID jab during the pandemic, ultimately brand-named Comirnaty.
Those two companies will have to reach into their coffers to compensate Moderna. The court said both Pfizer and BioNTech will be required to provide information on earnings that derived from the use of the patent in question; this will be used to determine how much they'll have to pay.
The ruling is subject to appeal. None of the three companies has yet commented publicly on it.
In addition to the compensatory payment, which might end up being rather large, Moderna establishes something of a precedent with this ruling. It should carry at least some weight in similar cases, should the company care to pursue them. Regardless, on its own the German court's decision is a clear legal victory, and it gives strength to the company's most critical intellectual property.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.